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httpsWHAT THIS PAPER ADDS
This study provides a detailed analysis of long-term follow up of patients discharged after type A and type B
acute aortic syndromes. In particular, data about aorta related events (death, re-interventions) and non-aorta
related events (cardiovascular and non-cardiovascular) were collected and analysed. Data collected over a
long time interval (16 years) were analysed.Background: The aim was to assess the long-term outcome of patients diagnosed with type A and type B acute
aortic syndromes (AAS) and the mortality risk predictors.
Methods: A single centre retrospective observational study was performed on consecutive patients diagnosed
with AAS and discharged between 2000 and 2016: 242 surgically treated type A, 87 uncomplicated, medically
treated type B, and 80 complicated type B who received endovascular/surgical/hybrid treatment. Follow up of
discharged patients (5  3.9 years) was almost complete by the end of the study (December 2017).
Results: The mean age was 65.3  12.5 years, and 70.2% were men. Long-term all cause mortality was 5.4 per
100 patients per year in surgically treated type A AAS patients and 6.7 per 100 patients per year in type B AAS
patients (p ¼ .236). The rates of major aorta related events were 6.1 per 100 patients per year and 13.4 per 100
patients per year, respectively (p < .001). Non-aorta related events during long-term follow up occurred in 18.2
per 100 patients per year in type A and 13.8 per 100 patients per year in type B (p ¼ .055). At the end of follow
up 279/409 (68.2%) patients (165/242 type A and 114/167 type B) experienced at least one event.
Conclusions: Among patients with either type A or type B AAS surviving the acute phase, the risk of adverse aorta
and non-aorta related events, including death, persists during follow up, so that eventually two thirds of patients
will experience at least one event. Notably, all cause mortality after type B AAS exceeds that of type A AAS after
three years.
 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.
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Acute aortic syndromes (AAS) include different conditions
(intramural haematoma, penetrating aortic ulcer, and aortic
dissection) that share aetiological substrates and clinical
manifestations.
In type A AAS emergency surgery is the standard treatment
and is associated with a 30 day mortality of around 30%.1,2
Thoracic endovascular aortic repair (TEVAR) has become the
treatment of choice for all type B AAS with clinical and/or
anatomical complications.3 Furthermore, recent data fromresponding author. Cardiology, Department of Experimental Diag-
and Specialty Medicine, Alma Mater Studiorum-University of
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://doi.org/10.1016/j.ejvs.2018.03.030multicentre randomised trials and from the International
Registry of Acute Aortic Dissection (IRAD) registry5 suggest
that TEVAR can offer long-term benefit in terms of aortic
events even in uncomplicated type B patients, and this has
been acknowledged in the most recent European guidelines.1
Although a number of studies have analysed long-term
aortic complications in AAS6,7 data regarding the incidence
of non-aorta related events in the long term are limited.
The aim was to assess the long-term outcome of patients
diagnosed with AAS, including all cause mortality, aorta and
non-aorta related events, aswell as risk predictors formortality.METHODS
Study design
The S. Orsola-Malpighi University Hospital is the referral
centre for AAS treatment in a metropolitan hospital
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(catchment area 1,000,000 inhabitants). The series includes
all consecutive patients with a final diagnosis of sponta-
neous AAS (aortic dissection, intramural haematoma,
penetrating aortic ulcer), with symptom onset <14 days,
referred between January 1, 2000, and December 31, 2016.
Follow up after discharge was obtained through sched-
uled 1, 6, and 12 month computed tomography (CT) scans
and visits, and yearly thereafter for both type A and type B
patients. For those patients who were not followed in the
centre, follow up information was obtained through tele-
phone calls. The follow up ended in December 2017. The
investigation conformed with the principles outlined in the
Declaration of Helsinki and the study was approved by the
local ethics committee.
Definitions
Major aorta related events included aorta specific mortality
(defined as death from documented aortic rupture, heart
failure secondary to cardiac tamponade or severe aortic
regurgitation, malperfusion, proximal extension in type B
patients, and peri-operative mortality), rehospitalisation for
aortic complications (progression of aortic pathology causing
malperfusion, increasing aortic diameter, progressive false
lumen dilation, aortic rupture, redissection, moderate/severe
aortic regurgitation) with or without re-intervention.
Non-aorta related events included non-aorta specific
mortality (cardiovascular [CV] and non-CV related), reho-
spitalisation for other CV causes (including acute coronary
syndrome [ACS], congestive heart failure, arrhythmia, ce-
rebrovascular accident, bleeding, and other CV causes), and
rehospitalisation for non-CV causes. Sudden death was
considered aorta related when preceded by signs or
symptoms suggestive of cardiac tamponade or aortic
rupture. Sudden death was considered cardiac non-aorta
related in the remaining cases.
Complications leading to invasive treatment in type B
patients included persistent or recurrent pain, uncontrolled
hypertension despite optimal medical treatment, malper-
fusion, early aortic expansion or signs of rupture such as
haemothorax, increasing periaortic effusion or mediastinal
haematoma.
ECG was considered to be ACS-like in the presence of 1
of the following characteristics: (a) ST segment elevation in
two contiguous leads with the cut off point 0.1 mV in all
leads other than V2V3, where the cut off point was
0.2 mV; (b) horizontal or down sloping ST segment
depression 0.1 mV in two contiguous leads; and (c) T
wave inversion 0.1 mV in two contiguous leads.8 Shock
was defined as a systolic blood pressure persistently lower
than 90 mmHg. GFR (glomerular filtration rate) was esti-
mated using the modified Modification of Diet in Renal
Disease equation.9
Statistical analysis
Categorical variables are expressed as percentages and
proportions, and continuous variables are reported asmean  SD. The chi-square test or the Fisher exact test (for
fewer than 5 observations) was used to compare groups for
categorical variables, and the two-tailed Student t test was
used for normally distributed continuous variables. The
BenjaminieHochberg procedure was used to control the
familywise error rate in multiple comparisons.
Cox regression was performed to identify predictors of
long-term outcome for patients discharged; non-correlated
variables with p < .2 at univariable analysis were included
in the multivariable analysis. Survival analyses were per-
formed using the KaplaneMeier method. For all statistical
comparisons p < .05 was considered significant. All ana-
lyses were performed with the STATA/SE 12.1 software
for Windows (StataCorp LP, College Station, TX, USA).RESULTS
The study population consisted of 553 consecutive patients
with a final diagnosis of spontaneous AAS (347 type A, 206
type B). Patents that died soon after admission and/or
those with surgical/endovascular indications who did not
undergo surgery because of excessive peri-operative risk
were excluded from follow up analyses.
Optimal treatment during the index hospitalisation
included surgery for type A AAS (295 patients, 85% of type
A patients), medical treatment for uncomplicated type B
AAS (91 patients, 44% of type B patients), and endovascular,
surgical or hybrid endovascular/surgical treatment for
complicated type B AAS (101 patients, 49% of type B pa-
tients). Among surgically treated type A patients 63% (186/
295) were DeBakey type I.
All follow up analyses were performed on patients who
received optimal treatment during the index hospitalisation
and were discharged after the acute phase: 409 overall, 242
type A, 87 uncomplicated type B, 80 complicated type B
(Supplementary Fig. 1). Average follow up of discharged
patients was 5  3.9 years (6  3.8 years for type A and
5  4.1 years for type B). The median follow up index was 1
(IQR 0.9e1) for the overall discharged patients, and for
both type A and type B subgroups.10Thirty day outcome
Details of surgical and endovascular treatments performed
during the index hospitalisation are reported in
Supplementary Table 1.
Of the 347 patients admitted with type A AAS, 85 died
(30 day mortality 24.5%) including 50 out of 295 who un-
derwent surgery (peri-operative mortality 16.9%). Of the
patients who did not undergo surgery because of excessive
surgical risk, 35/52 (67%) died at 30 days.
A total of 242 patients with type A AAS were discharged
and included in long-term follow up analyses.
Of the 206 type B AAS patients, 29 died (30 day mortality
14.1%); specifically, 19 of 101 (18.8%) complicated patients
who underwent endovascular/surgical/hybrid treatment
and three of 91 (3.3%) uncomplicated patients who
received medical treatment (p ¼ .001).
202 Anna Corsini et al.A total of 167 type B patients (87 uncomplicated, 80
complicated) survived the index hospitalisation and were
included in long-term follow up analyses.
Long-term outcome
Baseline characteristics of the study population are listed in
Table 1.
Fig. 1 shows all cause mortality of the overall population
according to Stanford subtype: while mortality of type A
patients was higher during the acute phase, the two survival
curves crossed around year 3, type B patients showing the
highest mortality at the end of follow up.Table 1. Characteristics of patients discharged after type A and type B
Variable Overall (N ¼ 40
Type of acute aortic syndrome
Aortic dissection 80.4% (329)
Intramural haematoma 12.7% (52)
Plaque rupture/ulceration 1.7% (7)




Age (years), mean  SD 65.3  12.5
Men 70.2% (287)
Hypertension or antihypertensive therapy 75.3% (308)
Hypercholesterolemia or lipid lowering drugs 26.7% (109)
Diabetes 5.4% (22)
Current smoking 27.1% (111)
Marfan syndrome 1.5% (6)
Bicuspid aortic valve 2.7% (11)
Aortic coarctation 0.2% (1)
Known thoracoeabdominal aortic aneurysm
(surgically treated or not) and/or previous AAS
14.4% (59)
Previous stroke 3.7% (15)
Coronary artery disease (history) 7.6% (31)
Disease complications
Pleural effusion 21% (86)
Periaortic effusion 14.9% (61)
Pericardial effusion 28.1% (115)
Cardiac tamponade 6.6% (27)
Moderate/severe aortic regurgitation 19.8% (81)
Shock within 12 h of admission 10.3% (42)
Stroke 3.7% (15)
Peri-/post-operative cerebral malperfusion 11.5% (47)
Peri-/post-operative visceral malperfusion 13.9% (57)
ACS-like electrocardiogram 18.8% (77)
Coronary ostial involvement 2.4% (10)
Creatinine at presentation (mg/mL), mean  SD 1.1  0.6
Medical therapy at discharge
Antiplatelet drugs 56.2% (230)
Anticoagulant drugs 27.8% (114)
Beta receptor blockers 81.9% (335)
ACEIs/ARBs 48.4% (198)
Calcium channel blockers 37.2% (152)
Diuretics 57.2% (234)
Other antihypertensive drugs 21.3% (87)
Statins 17.8% (73)
AAS ¼ acute aortic syndrome; ACEIs ¼ angiotensin converting enzyme
receptor blockers; SD ¼ standard deviation.Type A AAS
All cause mortality. Long-term all cause mortality in surgi-
cally treated type A AAS patients was 5.4/100 patients per
year (Fig. 2).
Table 2 reports the risk factors for long-term mortality in
patients discharged after type A AAS treated surgically. Af-
ter multivariable analysis, age (HR 1.06 for each 1 year in-
crease; 95% CI 1.03e1.08; p < .001), creatinine level at
presentation (HR 2.99; 95% CI 1.96e4.56; p < .001), and
peri/post-operative cerebral malperfusion (HR 2.08; 95% CI
1.14e3.78; p ¼ .016) remained independent predictors of
long-term mortality.AAS.
9) Type A 59% (N ¼ 242) Type B 41% (N ¼ 167) p
86.4% (209) 71.9% (120) <.001
9.9% (24) 16.8% (28) .058
1.2% (3) 2.4% (4) .619
2.5% (6) 8.9% (15) .007
64.9  12.1 65.9  12.9 .424
68.2% (165) 73.1% (122) .343
71.5% (173) 80.8% (135) .041
21.1% (51) 34.7% (58) .003
4.1% (10) 7.2% (12) .262
21.9% (53) 34.7% (58) .006
1.2% (3) 1.8% (3) .967
3.3% (8) 1.8% (3) .538
0% (0) 0.6% (1) .852
9.9% (24) 20.9% (35) .003
5.4% (13) 1.2% (2) .052
8.3% (20) 6.6% (11) .66
19% (46) 24.4% (40) .279
12.4% (30) 18.6% (31) .114
38.8% (94) 12.6% (21) <.001
11.2% (27) 0% (0) <.001
28.5% (69) 7.2% (12) <.001
15.7% (38) 2.4% (4) <.001
5.4% (13) 1.2% (2) .052
14.4% (35) 7.2% (12) .035
19.8% (48) 5.4% (9) <.001
21.9% (53) 9.9% (24) .074
4.1% (10) 0% (0) .02
1.1  0.4 1.2  0.8 .096
52.5% (127) 61.7% (103) .082
37.2% (90) 14.4% (24) <.001
76.9% (186) 89.2% (149) .002
47.9% (116) 49.1% (82) .895
26% (63) 53.3% (89) <.001
53.3% (129) 62.9% (105) .069
9.1% (22) 38.9% (65) <.001
16.5% (40) 13.8% (23) .535
inhibitors; ACS ¼ acute coronary syndrome; ARBs ¼ angiotensin
Figure 1. All cause mortality since hospitalisation according to
Stanford subtype excluding early, pre-treatment deaths and patients
with contraindication to the intervention (295 type A, 192 type B).
Long-term Follow up after Acute Aortic Syndromes 203Major aorta related events. The long-term rate of major
aorta related events after discharge was 6.1 per 100 pa-
tients per year (Fig. 2), including a 6.6% (16 patients) aorta
specific mortality (Table 3, Supplementary Fig. 2).
A total of 52 patients (21.5%) underwent re-intervention
on the aorta during follow up (Table 3): 37 patients for
progressive aortic dilation, five for aortic pseudoaneurysm,
two for severe aortic valve regurgitation, two for signs of
impending aortic rupture, two for recurrent type B AAS, one
for residual intimal flap in the aortic arch, one for residualFigure 2. Long-term outcome of discharged tysymptomatic type B intramural haematoma, one for renal
malperfusion, and one for endoleak.
Specifically, five of the 24 patients who underwent an
“elephant trunk” procedure experienced a step-up re-
intervention for dilatation of the descending aorta. As to
the three patients with isolated type A plaque rupture/ul-
ceration, one death was observed for an aortic cause
(haemoptysis with documented progression of the aortic
disease). This patient did not undergo further surgery as the
surgical risk was considered excessive, and the two surviv-
ing patients did not require further surgery.
Non-aorta related events. Non-aorta related events after
discharge occurred in 18.2 of 100 patients per year (Fig. 2),
including a 23.6% (57 patients) non-aorta related mortality
(Table 3, Supplementary Fig. 2).
Of the 57 patients who died of non-aorta related causes
during follow up, 16 died of non-aortic CV causes (7 of
stroke, 3 of infective endocarditis, 4 of sudden cardiac
death, 2 of heart failure), 13 of infection, 12 of cancer, and
16 of other causes.
Regarding rehospitalisation, 85 patients (35.1%) had a
rehospitalisation for non-aortic CV causes and 91 patients
(37.6%) for non-CV causes, mainly infection and cancer
(Table 3).
When considering the year of presentation (2000e2008
vs. 2008e2016), there were no differences in all cause
mortality (p ¼ .736) after long-term follow up
(Supplementary Fig. 3).pe A (242) and type B (167) AAS patients.
Table 2. Risk factors for long-term mortality of patients discharged after surgically treated type A AAS.
Variable Univariable analysis Multivariable analysis
HR (95% CI) p HR (95% CI) p
Age (for each one year increase) 1.06 (1.03e1.08) <.001 1.06 (1.03e1.08) <.001
Male gender 0.78 (0.48e1.25) .312
Hypertension (history) 2.54 (1.34e4.84) .004 1.88 (0.91e3.89) .086
Hypercholesterolemia 1.39 (0.8e2.4) .231
Diabetes 3.07 (1.23e7.66) .016
Current smoking 0.37 (0.16e0.87) .022
Known thoraco-abdominal aortic aneurysm (surgically treated
or not) and/or previous AAS
1.7 (0.84e3.44) .136
Previous stroke 0.97 (0.35e2.67) .958
Coronary artery disease (history) 1.3 (0.59e2.84) .506
Aortic bulb diameter at presentation (for each 1 mm increase) 1.02 (0.95e1.08) .537
Ascending aorta diameter at presentation (for each 1 mm increase) 1.01 (0.98e1.03) .471
Aortic arch diameter at presentation (for each 1 mm increase) 0.98 (0.91e1.05) .589
Descending aorta diameter at presentation (for each 1 mm increase) 1.01 (0.99e1.03) .143
DeBakey type I 1.04 (0.63e1.73) .851
Creatinine at presentation (for each 1 mg/mL increase) 2.96 (1.9e4.61) <.001 2.99 (1.96e4.56) <0.001
Ascending aorta þ arch replacement 0.83 (0.47e1.45) .517
Peri-/post-operative cerebral malperfusion 2.28 (1.3e4.01) .004 2.08 (1.14e3.78) .016
Peri-/post-operative visceral malperfusion 2.12 (1.29e3.49) .003
Shock 0.65 (0.32e1.31) .235
ACS-like ECG 1.15 (0.66e1.98) .61
Harrell’s C ¼ 76%. AAS ¼ acute aortic syndrome; ACS ¼ acute coronary syndrome; CI ¼ confidence interval; HR ¼ hazard ratio.
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All cause mortality. After discharge, long-term all cause
mortality for type B patients was 6.7 per 100 patients per
year; 5.9 per 100 patients per year for uncomplicated type B
patients and 7.7 per 100 patients per year in complicated
patients (p ¼ .351) (Fig. 3).
Older age (HR 1.06 for each 1 year increase; 95% CI
1.04e1.09; p < .001), creatinine at presentation (HR 1.29;
95% CI 1.01e1.63; p ¼ .037), and peri/post-operative
visceral malperfusion (HR 4.05; 95% CI 1.37e11.95;
p ¼ .011) remained independent predictors of long-term




Long-term outcome after discharge
Intervention/Re-intervention 27.4%
Re-hospitalization for aortic causes 30.1%
Re-hospitalization non-aortic CV causes: 29.8%
- Re-hospitalization for ACS 2.4% (
- Re-hospitalization for CHF 4.4% (
- Re-hospitalization for tachyarrhythmia/bradyarrhythmia 2.9% (
- Re-hospitalization for CVA 3.7% (
- Re-hospitalization for bleeding 3.2% (
- Re-hospitalization for other CV causes 13.2%
Re-hospitalization for non-CV causes 31.3%
All-cause mortality 30.6%
Aorta-related mortality 6.1% (
CV non-aorta-related mortality 8.1% (
Non-CV non-aorta-related mortality 16.4%
Any event 68.2%
ACS: acute coronary syndrome; CHF: congestive heart failure; CV: cardMajor aorta related events
After discharge, the long-term incidence of major aorta
related events was 13.4 per 100 patients per year; 12.3 per
100 patients per year in uncomplicated type B patients and
14.8 per 100 patients per year in complicated patients
(p ¼ .541), (Fig. 3). Aorta specific mortality was 2.3% (2
patients) in the uncomplicated group and 8.8% (7 patients)
in the complicated group (p ¼ .053), (Table 5,
Supplementary Fig. 2).
Among uncomplicated type B patients, who did not un-
dergo invasive treatment during the index hospitalisation,
31 (35.6%) were treated with an endovascular/surgical/l Type A Type B p
(72/487) 16.9% (50/295) 11.5% (22/192) 0.116
(112/409) 21.5% (52/242) 35.9% (60/167) 0.002
(123/409) 26% (63/242) 35.9% (60/167) 0.042
(122/409) 35.1% (85/242) 22.2% (37/167) 0.007
10/409) 2.1% (5/242) 2.9% (5/167) 0.786
18/409) 6.2% (15/242) 1.8% (3/167) 0.059
12/409) 3.7% (9/242) 1.8% (3/167) 0.404
15/409) 4.9% (12/242) 1.8% (3/167) 0.16
13/409) 4.1% (10/242) 1.8% (3/167) 0.3
(54/409) 14% (34/242) 11.9% (20/167) 0.645
(128/409) 37.6% (91/242) 22.2% (37/167) 0.001
(125/409) 30.2% (73/242) 31.1% (52/167) 0.92
25/409) 6.6% (16/242) 5.4% (9/167) 0.766
33/409) 6.6% (16/242) 10.2% (17/167) 0.264
(67/409) 16.9% (41/242) 15.6% (26/167) 0.816
(279/409) 68.2% (165/242) 68.3% (114/167) 0.928
iovascular; CVA: cerebrovascular accident.
Figure 3. Long-term outcome of discharged uncomplicated type B (optimal medical therapy group, 87 patients) or complicated type B
(endovascular/surgical/hybrid treatment group, 80 patients) AAS patients.
Table 4. Risk factors for long-term mortality of patients discharged after type B AAS.
Variable Univariable analysis Multivariable analysis
HR (95% CI) p HR (95% CI) p
Age (for each one year increase) 1.06 (1.03e1.09) <.001 1.06 (1.04e1.09) <.001
Male gender 0.75 (0.42e1.35) .35
Hypertension (history) 1.3 (0.58e2.91) .511
Hypercholesterolemia 0.9 (0.47e1.72) .756
Diabetes 2.63 (1.02e6.73) .044
Current smoking 0.59 (0.3e1.13) .114
Marfan syndrome 0.49 (0.06e3.76) .496
Known thoraco-abdominal aortic aneurysm (surgically
treated or not) and/or previous AAS
1.93 (1.05e3.54) .033
Coronary artery disease (history) 1.71 (0.73e4.02) .214
Aortic bulb diameter at presentation (for each 1 mm increase) 1.04 (0.99e1.1) .09
Ascending aorta diameter at presentation (for each 1 mm increase) 1.08 (1.03e1.13) <.001
Aortic arch diameter at presentation (for each 1 mm increase) 1.05 (0.99e1.11) .089
Descending aorta diameter at presentation (for each 1 mm increase) 1.05 (1.03e1.08) <.001
Creatinine at presentation (for each 1 mg/mL increase) 1.25 (1e1.56) .046 1.29 (1.01e1.63) .037
Endovascular/surgical/hybrid treatment 1.2 (0.69e2.07) .504
Peri-/Post-operative cerebral malperfusion 1.42 (0.56e3.57) .456
Peri-/Post-operative visceral malperfusion 2.01 (0.72e5.61) .179 4.05 (1.37e11.95) .011
Shock 1.59 (0.38e6.62) .521
ACS- like ECG 0.58 (0.24e1.37) .217
Harrell’s C ¼ 69%. AAS ¼ acute aortic syndrome; ACS ¼ acute coronary syndrome; CI ¼ confidence interval; HR ¼ hazard ratio.
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206 Anna Corsini et al.hybrid procedure during follow up (Table 5): 28 patients for
aortic dilation (with a maximum diameter exceeding
55 mm), three for signs of impending rupture.
In the complicated type B group, 29 patients (36.3%)
underwent re-intervention (Table 5): 14 patients for
descending aorta dilation distal to the endoprosthesis, 11
for endoleak, two for signs of impending rupture, one for
recurrent type A AAS, and one for symptomatic retrograde
extension of the aortic dissection. As for the four patients
with type B plaque rupture/ulceration, only three were
complicated at presentation and were treated with an
endoprosthesis, two died for non-aortic causes, and none
required surgical intervention or re-intervention.
Non-aorta related events. The long-term rate of non-aorta
related events after discharge was 13.8 per 100 patients per
year; 16.3 per 100 patients per year in the uncomplicated
group and 11.1 per 100 patients per year in the complicated
group (p ¼ .135) (Fig. 3). Non-aorta related mortality was
26.4% (23 patients) in the uncomplicated group and 25%
(20 patients) in the complicated group (p ¼ .861) (Table 5,
Supplementary Fig. 2).
Of the 43 patients who died of non-aorta related causes
during follow up, 17 died of non-aortic CV causes (8 pa-
tients suffered sudden cardiac death, 4 heart failure, 2
stroke, 1 acute myocardial infarction, 1 pulmonary embo-
lism, 1 haemorrhagic shock due to femoral puncture), nine
died of cancer, eight of infection, and nine of other causes.
As for rehospitalisations (Table 5), in the uncomplicated
group 27 patients (31%) were hospitalised for non-aortic CV
causes compared with 10 (12.5%) in the complicated group
(p ¼ .106). Also the rates of readmission for non-CV causes
did not differ significantly between the two groups: 24
patients (27.6%) in the uncomplicated group vs. 13 patients
(16.3%) in the complicated group (p ¼ .573).
Dividing the overall population of patients with type B
AAS into two groups according to the year of presentationTable 5. Outcome of patients after type B AAS according to therapeu
Variable Overall M
Short-term outcome
30 day mortality 11.5% (22/192) 3
Long-term outcome after discharge
Intervention/re-intervention 35.9% (60/167) 3
Rehospitalisation for aortic causes 35.9% (60/167) 3
Rehospitalisation for non-aortic CV causes 22.2% (37/167) 3
Rehospitalisation for ACS 2.9% (5/167) 5




Rehospitalisation for CVA 1.8% (3/167) 3
Rehospitalisation for bleeding 1.8% (3/167) 2
Rehospitalisation for other CV causes 11.9% (20/167) 1
Rehospitalisation for non-CV causes 22.2% (37/167) 2
All cause mortality 31.1% (52/167) 2
Aorta related mortality 5.4% (9/167) 2
CV non-aorta related mortality 10.2% (17/167) 9
Non-CV non-aorta related mortality 15.6% (26/167) 1
ACS ¼ acute coronary syndrome; CHF ¼ congestive heart failure; CV(2000e2008 vs. 2008e2016), there were no significant
differences in all cause mortality (p ¼ .484) at long-term
follow up (Supplementary Fig. 3).DISCUSSION
The present study provides a detailed analysis of contem-
porary long-term outcome of type A and type B AAS,
considering both aorta- and non-aorta related events. The
most significant findings are that:
1. All cause mortality after type B AAS exceeds that of type
A AAS after three years.
2. Among patients with either type A or type B AAS
surviving the acute phase, the risk of adverse aorta
and non-aorta related events, including death, persists
during follow up, so that eventually two thirds of
patients will experience at least one event.
3. Despite an initial conservative strategy, with only
complicated type B patients undergoing surgical or
endovascular treatment, 69% of patients presenting
with Type B AAS required surgical or endovascular
treatment considering the whole follow up.
The main clinical characteristics of the population are
similar to those of the IRAD registry (International Registry
of Acute Aortic Dissection),6,7 except for a lower prevalence
of Marfan syndrome. Among type A patients, surgical in
hospital mortality (17%) was similar to that reported in the
IRAD registry, but differed in not having a decline in surgical
mortality over time, probably because of the high volume
surgical expertise achieved at the centre since the early
2000s.
The surgical strategy at the centre aimed to remove the
primary entry tear, and is characterised by a high rate of
hemi-arch and arch replacement (combined with replace-
ment of the ascending aorta), preferably with open distaltic strategy at baseline.
edical therapy Medical therapy þ endovascular/
surgical/hybrid treatment
p
.3% (3/91) 18.8% (19/101) .001
5.6% (31/87) 36.3% (29/80) .255
6.8% (32/87) 35% (28/80) .393
1% (27/87) 12.5% (10/80) .106
.7% (5/87) 0% (0/80) .158
.3% (2/87) 1.3% (1/80) .746
.4% (3/87) 0% (0/80) .393
.4% (3/87) 0% (0/80) .393
.3% (2/87) 1.3% (1/80) .746
3.8% (12/87) 10% (8/80) .876
7.6% (24/87) 16.3% (13/80) .573
8.7% (25/87) 33.8% (27/80) .112
.3% (2/87) 8.8% (7/80) .053
.2% (8/87) 11.3% (9/80) .432
7.2% (15/87) 13.8% (11/80) .962
¼ cardiovascular; CVA ¼ cerebrovascular accident.
Long-term Follow up after Acute Aortic Syndromes 207anastomosis technique without aortic clamping. In the
current practice, if the aortic arch must be replaced end to
end anastomosis is performed between the prosthetic graft
and the aorta beyond the left subclavian artery, usually with
the “frozen elephant trunk” approach, in order to stabilise
the proximal portion of the descending aorta.11,12 However,
despite the “elephant trunk” technique being used
increasingly to treat complex pathologies of the aortic arch
and/or of the descending aorta, including AAS, the costs in
terms of increased acute phase morbidity (bleeding, stroke,
spinal cord injury, acute kidney injury) and mortality, and
the effective number of patients needing a second inter-
vention during follow up are still debated.13 Five of 24
patients treated with this strategy also needed an endo-
vascular re-intervention for dilation of the thoraco-
abdominal aorta during follow up.
Regarding the aortic valve, replacement was performed in
a high number of patients (109/295, 36.9%) while valve
reimplantation (David technique) was carried out only in
3.7% of cases (11 patients). This strategy has been shown to
be protective for long-term aortic valve re-intervention,
mainly for regurgitation,14 which occurred in three of the
patients.
In this series, despite 80% of patients undergoing surgery
that extended beyond the ascending aorta, involving the
aortic valve in 40%, the overall rate of long-term re-inter-
vention was 20%, and in most cases this was elective.
In this series, the risk of developing a type B AAS among
patients who previously underwent surgical treatment of
type A AAS appears to be low, involving two of 295 patients,
as is the risk of developing type A disease after type B AAS,
involving one of 161 patients. These patients had hyper-
tension as the single identified risk factor and no signs of
connective tissue disease.
The high rate of long-term non-aorta related events,
including mortality, is one of the main findings of the study.
During a mean follow up of 5 years, the non-aorta related/
aorta related events ratio was 3 in type A patients. Despite
the relatively low mean age of the population (around 65) a
moderately high rate of fatal non-CV events (cancer, infec-
tion) was observed.
In type B patients, in hospital mortality was higher among
complicated than uncomplicated patients (23.8% vs. 3.4%,
p < .001), and the trend was maintained during long-term
follow up, although the difference does not reach statistical
significance. Even though the usefulness of interventional
treatment for uncomplicated cases remains under
debate,4,5 an initial “conservative strategy” has been
adopted, with only complicated type B AAS patients un-
dergoing surgical or endovascular treatment during the
acute phase (49% in this series). Nevertheless, a consider-
ably high number of patients treated with optimal medical
therapy at the index hospitalisation required an interven-
tional approach for late complications, so that in the long-
term 69% of patients had undergone endovascular/surgi-
cal/hybrid treatment.15 The need for a re-intervention
among patients receiving interventional treatment in the
acute phase is not uncommon,16 and in the currentpopulation it reached 36.3%. The most common causes of
delayed operation/reoperation were progressive aortic
dilation in both groups. The majority of follow up in-
terventions were elective.
As with type A patients, those with type B AAS also
experience a high rate of non-aorta related events,
including mortality, so that after an average follow up of 5
years, the non-aorta related/aorta related events ratio is 1.
Despite the fact that this study was not designed to
investigate the mechanisms of the follow up events, it is
possible to hypothesise on the reasons behind some of the
coronary and cerebrovascular events that occurred. First,
the incidence of CV risk factors in the population is high
(and even higher in type B patients with respect to hyper-
tension, hypercholesterolaemia, and current smoking).
Moreover, it has been shown that the aortic prosthetic
material used in TEVAR can interfere with the generation
and propagation of reflected waves, potentially leading to
abnormal coronary perfusion and ventriculareaortic
coupling.17,18 It is also possible that the fear of redis-
section led to the avoidance of antiplatelet or anticoagulant
drugs in patients who, for various reasons, would have had
an indication for them.
Mortality independent predictors were related both to
general risk factors (age, renal function) and to aorta
specific complications such as cerebral and visceral
malperfusion.Conclusions and Clinical Implications
Despite type A AAS being a surgical emergency with a high
mortality in the acute phase, the morbidity and mortality of
type B AAS overtakes that of type A from the third year of
follow up onward. For both type A and B the clinical rele-
vance of non-aorta related events during long-term follow
up is high and increases progressively over time. Long-term
management of AAS patients discharged from hospital must
take these observations into consideration. A close coop-
eration between surgeons, radiologists and interventional
and clinical cardiologists is warranted.Study limitations
The small sample size and the single centre, retrospective
and non-randomised design of the study are the main
limitations of the analysis. Data regarding therapy and
blood pressure during follow up are missing, only the
therapy at discharge being known. Finally, a small difference
in follow up duration was found between type A and type B
patients.FUNDING
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